CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora™, in acute kidney injury are expected in the first half of 2026.